Summit Therapeutics

SMMT

Market cap $10.7B

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company's website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company.

SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit's Phase III Ri-CoDIFy study for the tre.

Cancer, type 2 diabetes, and IMIDs continue to spread across the globe, and while pharma stocks are back on Wall Street's radar, they still lag far behind AI-driven names. Also, many of them consistently beat consensus estimates and offer dividend yields that top most oil & gas and IT stocks. In this article, you'll discover my top 5 Big Pharma players.

Recursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process. Summit Therapeutics is focused on its lead oncology candidate, ivonescimab, aiming to disrupt the standard of care in lung cancer.

Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c.

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

After years of lagging the market, healthcare may be taking on a new role in investor portfolios.